Ignite Creation Date:
2025-12-25 @ 4:47 AM
Ignite Modification Date:
2025-12-26 @ 3:49 AM
Study NCT ID:
NCT04003818
Status:
TERMINATED
Last Update Posted:
2025-09-23
First Post:
2019-06-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Teicoplanin in CDAD
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003092', 'term': 'Colitis'}], 'ancestors': [{'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017334', 'term': 'Teicoplanin'}], 'ancestors': [{'id': 'D000077427', 'term': 'Lipoglycopeptides'}, {'id': 'D006020', 'term': 'Glycopeptides'}, {'id': 'D006001', 'term': 'Glycoconjugates'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 50}}, 'statusModule': {'whyStopped': 'Due to COVID-19 and great challenges during patient enrolment period, current status of this study is far behind the plan. The study cannot be completed according to the plan. Sanofi decides to terminate the study upon comprehensive assessment.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2020-05-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2021-03-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-09-18', 'studyFirstSubmitDate': '2019-06-06', 'studyFirstSubmitQcDate': '2019-06-28', 'lastUpdatePostDateStruct': {'date': '2025-09-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2019-07-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-01-21', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical cure rate', 'timeFrame': '2 days after 7-14 days treatment', 'description': 'Clinical cure is defined as: Resolution of diarrhea (ROD) (≤ 3 unformed bowel movement (UBM) per day for at least 2 consecutive days) on study treatment and maintained for 2 days after End of treatment (EOT), AND No additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) or fecal microbiota transplant (FMT) between first dose of study drug and 2 days after EOT (inclusive)'}, {'measure': 'Recurrence rate', 'timeFrame': 'Up to 10 weeks', 'description': 'Recurrence is defined as reappearance of diarrhea during the 8-week follow-up period.'}, {'measure': 'Time to resolution of diarrhea', 'timeFrame': 'Up to 10 weeks', 'description': 'Resolution of diarrhea (ROD) (≤ 3 unformed bowel movement (UBM) per day for at least 2 consecutive days) on study treatment and maintained for 2 days after end of treatment.'}], 'secondaryOutcomes': [{'measure': 'Incidence of nephrotoxicity', 'timeFrame': 'Until 10 weeks', 'description': 'Nephrotoxicity is defined as: serum creatinine increase of more than 0.5 mg/dL if the baseline serum creatinine was ≤ 3 mg/dL or a rise of \\> 1 mg/dL if the initial serum creatinine was \\> 3 mg/dL; or 50% increase from baseline; or a drop in calculated creatinine clearance using Cockroft-Gault formula of ≥ 50% from baseline.'}, {'measure': 'Incidence of hepatotoxicit', 'timeFrame': 'Up to 10 weeks', 'description': 'Hepatotoxicity is defined as: AST or ALT 3 times upper limit of normal or if AST or ALT baseline is abnormal, AST or ALT increase of ≥ 3 times the baseline and adverse events/ reactions using the MedDRA SMQ (Standardised MedDRA Query) "Hepatic Disorders".'}, {'measure': 'Incidence of thrombocytopenia', 'timeFrame': 'Up to 10 weeks', 'description': 'Thrombocytopenia is defined as: platelets \\< 100 000/mm3 or \\< 100 Giga/L'}, {'measure': 'Incidence of hearing and balance/vestibular disorders', 'timeFrame': 'Up to 10 weeks', 'description': 'Hearing and balance/vestibular disorders are defined as: identified via PT terms using MedDRA SMQ for "hearing and vestibular disorders" (narrow) and additionally the PT "balance disorder".'}, {'measure': 'Additional renal endpoints: renal failure, dialysis and renal replacement therapy', 'timeFrame': 'Until 10 weeks'}, {'measure': 'Any untoward adverse events/reactions', 'timeFrame': 'Up to 10 weeks'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Clostridium Difficile Infection-associated Diarrhea and Colitis']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.trialsummaries.com/Study/StudyDetails?id=25280&tenant=MT_SNY_9011', 'label': 'LPS16229 Plain Language Results Summary'}]}, 'descriptionModule': {'briefSummary': 'Primary Objective:\n\nExplore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis\n\nSecondary Objective:\n\nEvaluate the safety of teicoplanin in patients with Clostridium difficile infection-associated diarrhea and colitis', 'detailedDescription': 'Approximate 10 weeks'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion criteria :\n\n* Signed Informed Consent.\n* Male or female no less than 18 years of age.\n* Inpatient with a diagnosis of mild-moderate or severe CDAD (first occurrence or first recurrence within 3 months) with: Diarrhea: a change in bowel habits with \\> 3 liquid or unformed bowel movements (UBM) within 24 hours prior to enrollment, AND Positive C. difficile toxin test on a stool sample produced within 72 hours prior to enrollment.\n\nExclusion criteria:\n\n* More than one previous episode of CDAD in the 3-month period prior to enrollment.\n* Evidence of life-threatening or fulminant CDAD.\n* Likelihood of death within 72 hours from any cause.\n* History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea\n* Antimicrobial treatment active against CDAD administered for \\> 24 hours except for metronidazole treatment failures (MTF).\n* Known hypersensitivity or contraindication to teicoplanin.\n* Pregnant or nursing females.\n* Unable or unwilling to comply with all protocol requirements.\n* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."}, 'identificationModule': {'nctId': 'NCT04003818', 'briefTitle': 'Efficacy and Safety of Teicoplanin in CDAD', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sanofi'}, 'officialTitle': 'Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis', 'orgStudyIdInfo': {'id': 'LPS16229'}, 'secondaryIdInfos': [{'id': 'U1111-1230-0601', 'type': 'OTHER', 'domain': 'UTN'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Teicoplanin', 'description': 'teicoplanin, administered orally 100-200 mg, twice a day', 'interventionNames': ['Drug: TEICOPLANIN']}], 'interventions': [{'name': 'TEICOPLANIN', 'type': 'DRUG', 'description': 'Pharmaceutical form:solution for oral administration Route of administration: oral', 'armGroupLabels': ['Teicoplanin']}]}, 'contactsLocationsModule': {'locations': [{'city': 'China', 'country': 'China', 'facility': 'investigational site CHINA'}], 'overallOfficials': [{'name': 'Clinical Sciences & Operations', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Sanofi'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}